Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001)

Diagnostic Microbiology and Infectious Disease

Volumn 47, Issue 1, 2003, Pages 361-364

  Sader, Helio S ^a,b   Biedenbach, Douglas J ^a   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; CEFAZOLIN; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TIMENTIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; ASIA; BACTERIUM ISOLATE; CITROBACTER; CONTROLLED STUDY; DILUTION; DRUG ACTIVITY; DRUG MONITORING; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; DRUG USE; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EUROPE; HAFNIA ALVEI; HOSPITALIZATION; IN VITRO STUDY; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; NORTH AMERICA; PANTOEA; PRIORITY JOURNAL; PROTEUS MIRABILIS; PROVIDENCIA; SALMONELLA; SERRATIA; SHIGELLA; SOUTH AND CENTRAL AMERICA; YERSINIA;

EID: 0042328117     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(03)00052-X     Document Type: Article

References (15)

1. Ali M.Z., Goetz M.B. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 24:1997;796-809.
2. Barradell L.B., Bryson H.M. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 47:1994;471-505.
3. Diekema D.J., Pfaller M.A., Jones R.N., Doern G.V., Winokur P.L., Gales A.C., Sader H.S., Kugler K., Beach M. Survey of bloodstream infections due to gram-negative bacilli Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997 . Clin Infect Dis. 29:1999;595-607.
4. Harris A.D., Smith D., Johnson J.A., Bradham D.D., Roghmann M.C. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis. 1:2002;34. 340-345.
5. Jones R.N. Summation β-lactam resistance surveillance in the Asia-Western Pacific region . Diagn Microbiol Infect Dis. 35:1999;333-338.
6. Jones R.N. Resistance patterns among nosocomial pathogens. Trends over the past few years. Chest. 119:2001;397S-404S.
7. Jones R.N. Microbiology of newer fluoroquinolones Focus on respiratory pathogens . Diagn Microbiol Infect Dis. 44:2002;213-220.
8. Jones R.N., Varnam D.J. Antimicrobial activity of broad-spectrum agents tested against gram-negative bacilli resistant to ceftazidime Report from the SENTRY Antimicrobial Surveillance Program (North America, 2001) . Diagn Microbiol Infect Dis. 44:2002;379-382.
9. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 118:2000;146-155.
10. National Committee for Clinical Laboratory Standards. (2003). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-sixth edition. Approved document M7-A6. Wayne, PA:NCCLS.
11. National Committee for Clinical Laboratory Standards. (2003). Performance standards for antimicrobial susceptibility testing, 13th informtional supplement M100-S13. Wayne, PA:NCCLS.
12. Perry C.M., Ormrod D., Hurst M., Onrust S.V. Gatifloxacin A review of its use in the management of bacterial infections . Drugs. 62:2002;169-207.
13. Scheld W.M. Maintaining fluoroquinolone class efficacy Review of influencing factors . Emerg Infect Dis. 9:2003;1-9.
14. Troillet N., Samore M.H., Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa Risk factors and antibiotic susceptibility patterns . Clin Infect Dis. 25:1997;1094-1098.
15. Zhanel G.G., Ennis K., Vercaigne L., Walkty A., Gin A.S., Embil J., Smith H., Hoban D.J. A critical review of the fluoroquinolones Focus on respiratory infections . Drugs. 62:2002;13-59.